



The Nifty previous session ended 0.94% down at 17639.55. It opened on a negative note and remained choppy with a negative bias towards finishing off with a bearish candle. Midterm descending trend line resistance placed around 18100 remained unharmed. Hence, staying cautious is highly recommended. Immediate resistance is placed around 17800 levels. Failing to breakout may again push the Benchmark Index towards 17550 and 17400 levels. The Nifty Immediate trading range likely to be 17550-17800.

On the Nifty hourly chart, down trending leading indicators suggesting range bound oscillation with a negative bias below the 17800 levels.

Nifty patterns on multiple periods suggesting; it ended the day on a bearish note, which may continue in coming sessions as well. Downside supports are placed around 17550 and 17400 levels.

### Nifty Crucial Supports & Resistances-

**Supports- 17550, 17400 Resistances- 17800, 17900**

### Open Positional Calls-

T+7 POSITIONAL BUY-

| Cash Segment | INDIGO @ 1970-1950, TGT- 2060, Closing SL- above 1900

T+7 BUY-

| Cash Segment | HUL @ 2090-2080, TGT- 2180, Closing SL- Below 2130

T+5 BUY-

| Cash Segment | LUPIN @ 785-780, TGT- 820, Closing SL- Below 760

T+3 BUY-

| Cash Segment | HCL TECH @ 1185-1180, TGT- 1220, Closing SL- Below 1160

T+14 INST POSITIONAL BUY-

| Cash Segment | TATA CONSUMER @ 800 -790, TGT- 855, Closing SL- below 765

T+14 INST POSITIONAL BUY-

| Cash Segment | SAIL @ 111-110, TGT- 120, Closing SL- below 100

Key Contents	Page No.
Domestic News	4

## Nifty Intraday Chart



## Market in Retrospect

India's stock benchmarks fell for the third day, the longest losing streak in nearly two weeks, dragged by energy, consumer durables and oil & gas stocks.

Nifty index ended 0.94% lower at 17,808. The broader markets represented by the Nifty 500 Index ended 0.83% lower, ending at 15,201. Among the sectorial indices, Nifty Pharma was the top gainer, gaining by 0.41%, followed by Nifty Realty which was gaining by 0.03%. Nifty Energy was the top loser, losing by 1.70%.

Axis Bank was the top gainer, gaining by 2.38%, followed by Divi's Lab and HUL which was gaining by 1.40% & 1.06% respectively. Adani Ports & SE was the top loser, losing by 3.82%, followed by Titan and HDFC which fell by 3.22% & 2.89% respectively.

The Advance : Decline ratio stood at 922:1230

## Market Turnover (In Crore) 07-04-2022

Name	Last	Previous
NSE Cash	79373.31	76500
NSE F&O	20949344.77	10365936.93
BSE Cash	8,891.33	5,960.59
BSE F&O	*NA	197.96

## FII Derivatives Flow (In Crore) 06-04-2022\*

Instrument	Purchase	Sale	Net
Index Future	4278.92	4405.19	126.27
Index Option	770739.97	773060.84	2320.87
Stock Future	13776.86	15580.72	1803.86
Stock Option	10182.63	10080.36	102.27

## Institutional Flow (In Crore) 06-04-2022\*

Institution	Purchase	Sale	Net
FII	6324.77	8604.74	2279.97
DII	6961.91	6338.99	622.92

\*Data not updated till 6PM

## NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Axis Bank	2.38	4.07	9820244	11604050
Divi'S Laboratories	1.40	1.05	387968	432588
HUL	1.06	5.67	1824732	1792461
Dr. Reddy'S Lab	0.95	0.51	279402	415436
ICICI Bank	0.94	2.50	15087175	14341190

## NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Power Grid Corp	2.24	6.71	8935434	14132800
ONGC	2.29	3.02	24550313	22525720
HDFC	2.89	3.02	8094839	10443640
Titan	3.22	3.07	2785215	1295739
Adani Ports & SE	3.82	5.58	11662093	11180990

## Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>  
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.asp>

## Sensex Intraday Chart



## Market in Detailed (Updated after 4:00 PM)

### Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	59034.95	575.46	0.97	0.80	10.50	1.19	18.67
Nifty	17639.55	168.10	0.94	1.00	10.15	0.97	18.59
BSE M Cap	25069.81	105.98	0.42	3.99	13.39	1.58	21.38
BSE S Cap	29474.70	221.24	0.75	4.46	14.77	1.86	38.42
Nifty MC 100	30911.30	317.90	1.02	4.11	15.06	0.64	27.03
BSE Auto	24631.21	203.62	0.82	2.42	13.67	3.69	10.01
BSE Capgoods	28615.71	125.93	0.44	4.03	11.30	1.63	35.42
BSE FMCG	13843.77	3.05	0.02	3.82	11.62	0.67	7.44
BSE Metal	23043.78	342.34	1.46	3.02	5.43	16.07	47.31
BSE Oil&Gas	19425.22	516.95	2.59	3.65	8.75	5.34	29.94
BSE Healthcare	24850.49	108.11	0.44	2.25	9.55	3.06	12.30
BSE Power	4456.66	66.64	1.47	10.21	16.85	24.46	75.43
BSE Realty	3761.60	1.09	0.03	2.17	20.31	2.37	42.80
BSE ConsDur	42732.70	861.71	1.98	1.09	6.53	6.07	32.47
BSE Bank	43055.21	26.65	0.06	3.12	14.12	0.02	15.42
BSE IT	35700.79	368.76	1.02	1.93	6.02	4.18	29.09

### Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	2.62	0.02	0.73	11.91	47.54	48.49	56.31
UK	1.73	0.03	1.82	7.70	32.98	47.20	124.32
Brazil	5.28	0.10	1.91	4.57	4.80	9.84	25.55
Japan	0.23	0.01	4.90	5.91	58.50	66.43	135.35
Australia	2.91	0.02	0.58	2.61	36.42	57.09	66.51
India	6.91	0.00	0.04	1.14	0.38	5.72	13.70
Switzerland	0.68	0.00	0.30	12.79	273.08	4750.00	341.64
Germany	0.67	0.03	3.86	22.63	4580.00	1662.79	307.41

### Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	75.96	0.20	0.26	0.23	1.32	2.18	1.84
USD Index	99.66	0.06	0.06	1.37	0.36	4.11	7.79
YUAN	6.36	0.00	0.03	0.34	0.65	0.25	2.84
GBP	1.31	0.00	0.13	0.40	0.14	3.69	4.74
EUR	1.09	0.00	0.21	1.34	0.60	3.88	8.00
YEN	123.92	0.12	0.10	1.79	6.94	6.75	11.35

### Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2128.00	85.00	3.84	9.75	4.79	7.03	0.05
Baltic Dirty	1547.00	78.00	5.31	20.95	1.98	119.43	129.19
SG Dubai HY	18.79	1.82	10.72	53.39	28.70	194.05	2584.29

### Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	34496.51	144.67	0.42	2.08	5.12	4.79	3.14
Nasdaq	13888.82	315.35	2.22	3.83	8.24	7.01	1.46
S&P 500	4481.15	43.97	0.97	2.64	6.67	4.19	9.83
FTSE100	7578.70	8.32	0.11	0.85	8.91	1.26	10.08
CAC40	6544.58	45.71	0.70	1.73	9.40	9.35	6.75
DAX	14220.07	70.70	0.50	1.33	10.81	10.82	6.29
Mexico IPC	55438.73	108.56	0.20	0.67	5.98	4.20	15.74
Brazil Bovespa	118227.8	0.00	0.00	1.69	5.95	15.10	0.51
Russian RTS	1094.29	59.73	5.77	7.17	16.82	29.17	23.43
Japan Nikkei	26888.57	461.73	1.69	3.35	8.46	5.58	9.49
Hang Seng	21808.98	271.54	1.23	1.90	5.02	7.17	24.82
Taiwan Index	17178.63	343.87	1.96	2.11	2.10	5.45	1.49
Shanghai Comp	3236.70	46.73	1.42	1.02	1.73	9.58	7.06
KOSPI	2695.86	39.17	1.43	2.24	2.80	8.77	14.23
Malaysia KLCI	1600.79	3.93	0.24	0.85	3.49	3.74	0.10
Jakarta Comp	7127.37	23.15	0.33	0.79	4.60	6.36	17.39
Philippine SE	6926.03	183.23	2.58	3.85	0.74	1.21	5.82
Thai Exch	1682.41	18.77	1.10	0.94	3.91	1.50	7.93

### Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	98.23	1.89	1.96	2.15	17.82	24.36	64.16
BRENT Crude	102.92	1.73	1.71	1.82	13.52	28.89	71.68
Natural Gas	6.19	0.15	2.52	9.55	27.23	67.73	151.98

### LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1929.05	3.51	0.18	0.44	3.47	7.36	11.00
Silver(\$/Ounce)	24.47	0.01	0.05	1.29	4.64	9.41	2.69
Aluminium	3416.26	27.24	0.79	3.40	11.90	17.43	51.87
Copper	10286.75	146.25	1.40	0.71	3.88	7.80	13.62
Zinc	4294.25	36.66	0.85	2.98	5.48	20.02	53.05
Lead	2400.00	25.29	1.04	1.01	2.23	3.09	23.33

### Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	229.30	1.70	0.75	1.28	2.25	3.78	68.48
Cotton	135.29	0.40	0.29	0.29	15.69	19.85	69.81
Sugar	19.71	0.12	0.61	1.13	2.28	10.73	34.82
Wheat	1038.75	0.50	0.05	3.26	19.73	36.59	65.34
Soybean	1626.25	6.75	0.42	0.49	2.00	14.63	31.63

### **Bank of Maharashtra to divest entire 4% stake in ISARC**

Bank of Maharashtra on Thursday said it will divest its entire stake of 4 per cent in India SME Asset Reconstruction Company for nearly Rs 4 crore. Bank of Maharashtra (BoM) has executed a share purchase agreement dated April 6, 2022 for sale of entire equity stake of 4 per cent in India SME Asset Reconstruction Company Ltd (ISARC). The bank's 4 per cent stake, equivalent to 40,00,000 equity shares, will be sold at Rs 9.80 per share for a cash consideration for Rs 3.92 crore. The stake sale is subject to RBI approval for change in sponsor shareholder of ISARC. The transaction is expected to be completed by the end of December, 2022. ISARC's total income stood at Rs 11.09 crore in the fiscal ended March 2021, and net profit was Rs 0.36 crore. It had reported losses of Rs 8.39 crore in FY20 and Rs 9.21 crore in FY19.

### **Bandhan-led group to buy IDFC MF, deal valued at INR4,500 crore**

Bandhan Financial Holdings won the bid to buy IDFC Asset Management Company in a deal valued at INR4,500 crore, marking the entry of a financier that began its life as a bottom-of-the-pyramid lender into the ritzy business of asset management dominated by bulge-bracket financial groupings such as ICICI, HDFC and the State Bank of India. This is the largest deal to date in the Indian asset management space.

### **HDFC Bank plans to raise INR50, 000 crore through bond sale to back its big bang merger**

HDFC Bank will decide later this month on garnering about INR50,000 crore to help meet higher reserve requirements ahead of its proposed merger with HDFC Ltd. The estimated requirement was more than INR80,000 crore and the bank, India's most valued, already has some excess bonds in its portfolio. The bank would deliberate on the fundraising proposal at its upcoming board meeting on April 16.

### **India's sugar sales to race to record high as summer demand peaks**

India's sugar consumption is set to hit record highs in the current summer season as demand from bulk consumers such as cold drink and ice cream-makers rises after the lifting of COVID-19 restrictions. India's sugar consumption in the 2021/22 marketing year that ends on Sept. 30 is set to rise by nearly 3% from a year ago to an all-time high of 27.2 million tonnes, according to the Indian Sugar Mills Association (ISMA). Exports are also expected to reach record levels, with Indian mills having already signed contracts to ship 7.2 million tonnes of sugar overseas in the 2021/22 marketing year.

### **NLC India's power generation rises 19 pc to 2,920 cr units in FY22**

NLC India Ltd has registered an 18.64 per cent rise in power generation at 2,920 crore units in FY22. A new record has been created in terms of electricity generation, with the power stations of NLC India Ltd and its subsidiaries together generating 2,920 crore units of electricity (29.20 billion units) during 2021-22. The company and its subsidiaries have also exported 2,589 crore units of power during the year under review, which was 19.75 per cent higher than the preceding year.

### **Lupin launches generic contraceptive drug in US**

Lupin has launched Merzee capsules, a medication used to prevent pregnancy, in the US market. The Mumbai-based drug maker has launched the product in the US market under exclusive license, marketing and distribution agreement with Slayback Pharma LLC. Slayback had earlier launched this product in the US in February 2021. Merzee (norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules), 1 mg/20 mcg is a generic equivalent of Allergan Pharmaceuticals' Taytulla capsules. As per IQVIA MAT February 2022 data, Norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, 1 mg/20 mcg had estimated annual sales of USD 90 million in the US.

### **Lupin completes acquisition of portfolio of brands from Anglo-French Drugs & Industries**

Drug maker Lupin has completed the acquisition of a portfolio of brands from Anglo-French Drugs & Industries Limited (AFDIL) and its associates. The acquisition will strengthen the company's India formulation business by adding a fast-growing portfolio of vitamins, minerals, supplements and neurological products. The acquisition of the AFDIL brands takes the company further in shaping its portfolio to emerge as a leading pharmaceutical company in India. The drug maker will have a stronger market presence, providing healthcare professionals and patients with a more meaningful and comprehensive product offering.

### **Alembic Pharma gets tentative USFDA nod for generic version of Dabigatran Etxilate capsules**

Alembic Pharmaceuticals Ltd has received tentative approval from the US health regulator for its generic version of Dabigatran Etxilate capsules indicated for reduction of risk of stroke and prevention of blood clots. The tentative approval by the US Food & Drug Administration (USFDA) is for the abbreviated new drug application (ANDA) for Dabigatran Etxilate capsules of strengths 75 mg, 110 mg, and 150 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug (RLD) product Pradaxa Capsules, 75 mg, 110 mg, and 150 mg of Boehringer Ingelheim Pharmaceuticals, Inc (Boehringer). Dabigatran Etxilate capsules, are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients, treatment of deep venous thrombosis and pulmonary embolism in adult patients, reduction in the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients, prophylaxis of deep vein thrombosis and pulmonary embolism in adult patients following hip replacement surgery.



### CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Arihant Institute Ltd	Corporate meeting effective 08-04-22
Filatex India Ltd	4.250 Mln stock buyback effective 08-04-22

### Domestic Events

- India RBI Interest Rate Decision.
- India Foreign Exchange Reserve for April 01, 2022.

### Global Events

- Japan Consumer Confidence for March 2022.

### **Analyst Certification:**

We /I, Jaydeb Dey and Shreyansh N. Mehta Research Analyst(S) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### **Terms & Conditions and Other Disclosures:**

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document

to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report or at the time of Public Appearance.

SMIFS does not have proprietary trades but may at a future date, opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/short position in the above Scrip(s) and therefore should be considered as interested.

The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing, however the same shall have no bearing whatsoever on the specific recommendations made by the analysts, as the recommendations made by the analysts are completely independent views of the Associates of SMIFS even though there might exist an inherent conflict of interest in some of the stocks mentioned in the Research Report.

The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.



SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at [www.nseindia.com](http://www.nseindia.com) and/or [www.bseindia.com](http://www.bseindia.com), [www.mcxindia.com](http://www.mcxindia.com) and/or [www.icex.com](http://www.icex.com).

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

### Specific Disclosures

- SMIFS, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- SMIFS, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company.
- SMIFS, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months.
- SMIFS, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as director/officer/employee in the subject company
- SMIFS has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- SMIFS has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- SMIFS has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months.
- SMIFS has not received any compensation or other benefits from third party in connection with the research report.
- SMIFS has not engaged in market making activity for the subject company

Analyst holding in stock: **NO**

---

### Key to SMIFS Investment Rankings

Buy: Return >15%, Accumulate: Return between 5% to 15%, Reduce: Return between -5% to +5%, Sell: Return < -5%

---

### Contact us:

**SMIFS Limited.** (<https://www.smifs.com/>)

### Compliance Officer:

**Sudipto Datta,**

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5401 /91 33 6634 5401

Email Id.: [compliance@smifs.com](mailto:compliance@smifs.com)

---